<DOC>
	<DOCNO>NCT01994941</DOCNO>
	<brief_summary>This study aim compare outcome genotype guide versus clinical guide approach selection oral P2Y12 receptor blocker Chinese patient suffer acute coronary syndrome .</brief_summary>
	<brief_title>Genotype Guided Versus Conventional Approach Selection Oral P2Y12 Receptor Blocker Chinese Patients Suffering From Acute Coronary Syndrome</brief_title>
	<detailed_description>Acute coronary syndrome ( ACS ) disease high mortality , morbidity economic burden . Usually , cause ischemic heart disease atherosclerotic plaque rupture coronary artery cause platelet activation , aggregation thrombus formation . For decade , antiplatelet agent cornerstones management ACS dual antiplatelet therapy aspirin P2Y12 receptor blocker standard care patient ACS without percutaneous coronary intervention . However , increase evidence show clopidogrel , type thienopyridine , wide inter-individual variability pharmacokinetic pharmacodynamic action lead suboptimal antiplatelet effect especially Asian population . Cytochrome P450 2C19 important enzyme thienopyridine metabolism genetic polymorphism CYP2C19 demonstrate associate clopidogrel resistance ischemic event post percutaneous coronary intervention ( 1-3 ) . The prevalence LOF allele CYP2C19 high Chinese Caucasians ( 4 ) may lead high degree clopidogrel resistance Chinese patient document previous study ( 5 ) study another Asian country ( 6 ) In view potential limitation clopidogrel ACS treatment , American European guideline recommend use new P2Y12 blocker ticagrelor ( 7 ) ACS patient . Though agent well anti-ischemic effect , associate increase bleed risk especially Chinese patient consider prone bleeding complication . As result , local physician reluctant use potent antiplatelet agent despite proven clinical efficacy Caucasian study . Evidence show correlation CYP2C19 genotype , platelet reactivity , clinical outcome currently CYP2C19 genotype emerge target pharmacogenomic approach guide use antiplatelet agent . With advent rapid genotyping technology ( 8 ) , anticipated appropriate drug give appropriate patient . Verigene ( Nanosphere , Northbrook , IL ) FDA approve microarray-based genotyping assay rapid detection cytochrome P450 2C19 polymorphism whole blood use nanoparticle probe . It utilise whole blood detection single nucleotide polymorphism result available 2-4 hour . With proper train handling , accuracy expect &gt; 99 % . ( 9 , 10 )</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Age 18 year Diagnosis Acute Coronary Syndrome P2Y12 receptor blocker na√Øve plan load dose P2Y12 receptor blocker Chronic renal failure dialysis plan dialysis within 1 year Serious hepatic disease Active bleeding disorder Contraindicated allergic Clopidogrel ticagrelor History intracranial bleed Women pregnant childbearing potential use adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Acute Coronary Syndrome</keyword>
	<keyword>Platelet Reactivity</keyword>
	<keyword>P2Y12 Receptor Blocker</keyword>
	<keyword>CYP2C19 Genotyping</keyword>
</DOC>